JP2024541924A - Ｐｏｅｇｍａベース脂質ナノ粒子 - Google Patents

Ｐｏｅｇｍａベース脂質ナノ粒子 Download PDF

Info

Publication number
JP2024541924A
JP2024541924A JP2024524728A JP2024524728A JP2024541924A JP 2024541924 A JP2024541924 A JP 2024541924A JP 2024524728 A JP2024524728 A JP 2024524728A JP 2024524728 A JP2024524728 A JP 2024524728A JP 2024541924 A JP2024541924 A JP 2024541924A
Authority
JP
Japan
Prior art keywords
lipid
mol
poegma
mrna
lipid nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541924A5 (https=
JPWO2023076902A5 (https=
Inventor
アシュトッシュ チルコティ
ソウメン サハ
パルル シロヒ
アンガス ハックナル
ソナル デシュパンデ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2024541924A publication Critical patent/JP2024541924A/ja
Publication of JP2024541924A5 publication Critical patent/JP2024541924A5/ja
Publication of JPWO2023076902A5 publication Critical patent/JPWO2023076902A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024524728A 2021-10-25 2022-10-25 Ｐｏｅｇｍａベース脂質ナノ粒子 Pending JP2024541924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271595P 2021-10-25 2021-10-25
US63/271,595 2021-10-25
PCT/US2022/078659 WO2023076902A1 (en) 2021-10-25 2022-10-25 Poegma-based lipid nanoparticles

Publications (3)

Publication Number Publication Date
JP2024541924A true JP2024541924A (ja) 2024-11-13
JP2024541924A5 JP2024541924A5 (https=) 2025-10-31
JPWO2023076902A5 JPWO2023076902A5 (https=) 2025-10-31

Family

ID=86158533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524728A Pending JP2024541924A (ja) 2021-10-25 2022-10-25 Ｐｏｅｇｍａベース脂質ナノ粒子

Country Status (6)

Country Link
US (1) US20250049729A1 (https=)
EP (1) EP4422605A4 (https=)
JP (1) JP2024541924A (https=)
CN (1) CN118201605A (https=)
CA (1) CA3236153A1 (https=)
WO (1) WO2023076902A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117562869B (zh) * 2023-05-05 2024-07-16 中南大学湘雅医院 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用
WO2025067389A1 (en) * 2023-09-28 2025-04-03 Immorna (hangzhou) Biotechnology Co., Ltd. Lipid complex nanoparticle for lung-targeted delivery of nucleic acid therapeutic agent
WO2025081189A1 (en) * 2023-10-12 2025-04-17 Georgia Tech Research Corporation Methods and compositions for lipid nanoparticle (lnp) mediated delivery of mrna encoded synthetic antigens for universal tumor targeting by car t cells
CN118001253A (zh) * 2024-02-07 2024-05-10 北京大学 一种肾脏靶向mRNA-LNP递送技术和疾病治疗方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799565B2 (en) * 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US8497356B2 (en) 2009-02-17 2013-07-30 Duke University Biomolecule polymer conjugates and methods for making the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017112825A2 (en) 2015-12-21 2017-06-29 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2020051220A1 (en) 2018-09-04 2020-03-12 The Board of the Regents of the University of Texas System Compositions and methods for organ specific delivery of nucleic acids
CN112996519B (zh) * 2018-09-04 2025-02-28 德克萨斯大学系统董事会 用于核酸的器官特异性递送的组合物和方法
AU2021232069A1 (en) * 2020-03-05 2022-11-03 Flagship Pioneering Innovations Vi, Llc Host defense suppressing methods and compositions for modulating a genome
MX2023000806A (es) * 2020-07-17 2023-04-11 Generation Bio Co Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos.
CN112961065B (zh) * 2021-02-05 2023-03-14 嘉晨西海(杭州)生物技术有限公司 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
WO2022212911A1 (en) 2021-04-01 2022-10-06 Duke University Poegma copolymer conjugates and methods of treating diseases

Also Published As

Publication number Publication date
US20250049729A1 (en) 2025-02-13
CN118201605A (zh) 2024-06-14
WO2023076902A1 (en) 2023-05-04
EP4422605A4 (en) 2025-06-18
EP4422605A1 (en) 2024-09-04
CA3236153A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP2024541924A (ja) Ｐｏｅｇｍａベース脂質ナノ粒子
US9080186B2 (en) Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
EP2304026A2 (en) Nanoparticle compositions for nucleic acids delivery system
JP2012509272A (ja) 核酸送達系のための放出性カチオン脂質
JP2012509258A (ja) 核酸送達系のための分岐カチオン性脂質
JP2012509273A (ja) 核酸送達系のための放出可能融合性脂質
CN103189057B (zh) 大环脂类化合物及其应用
EP4520349A1 (en) Interfering rna for inhibiting b7-h3 gene expression and use thereof
WO2022251959A1 (en) Dna vector delivery using lipid nanoparticles
WO2010057150A1 (en) Releasable polymeric lipids for nucleic acids delivery systems
US20250099393A1 (en) Ionizable lipids, lipid nanoparticles, and uses thereof
WO2024086929A1 (en) Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
EP4626400A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
EP4630061A1 (en) Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid
CN120271651A (zh) 一种用于核酸递送的可电离阳离子脂质化合物和组合物及其应用
WO2026090175A2 (en) Propargyl amino-ionizable lipid compounds, lipid nanoparticles (lnps), and methods of making and using same for gene editing
CN121872965A (zh) 脂质化合物和脂质纳米颗粒组合物
CN121698795A (zh) 脂质化合物和脂质纳米颗粒组合物
CN121872927A (zh) 脂质化合物和脂质纳米颗粒组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251023